Search

Your search keyword '"Kikuchi, Kan"' showing total 275 results
Start Over Author "Kikuchi, Kan"
275 results on '"Kikuchi, Kan"'

1. Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients

Author

Yoshifuji, Ayumi, Toda, Masataro, Oyama, Emi, Nakayama, Tetsuo, Mise-Omata, Setsuko, Kikuchi, Kan, Yoshizawa, Mamoru, Kato, Naohiko, Wakai, Haruki, Koibuchi, Kiyoto, Morimoto, Kohkichi, Uwamino, Yoshifumi, Namkoong, Ho, Shibata, Ayako, Wakabayashi, Kaoru, Fujino, Motoko, Komatsu, Motoaki, Mochizuki, Naoki, Kondo, Norihiko, Yoshimura, Akihiko, Hasegawa, Naoki, and Ryuzaki, Munekazu

Published
2024
Full Text
View/download PDF

9. Annual dialysis data report 2019, JSDT Renal Data Registry

Author

Hanafusa, Norio, Abe, Masanori, Joki, Nobuhiko, Ogawa, Tetsuya, Kanda, Eiichiro, Kikuchi, Kan, Goto, Shunsuke, Taniguchi, Masatomo, Nakai, Shigeru, Naganuma, Toshihide, Hasegawa, Takeshi, Hoshino, Junichi, Miura, Kenichiro, Wada, Atsushi, and Takemoto, Yoshiaki

Published
2023
Full Text
View/download PDF

12. Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy

Author

Yoshifuji, Ayumi, Ryuzaki, Munekazu, Uehara, Yuki, Ohmagari, Norio, Kawai, Toru, Kanno, Yoshihiko, Kikuchi, Kan, Kon, Hiroshi, Sakai, Ken, Shinoda, Toshio, Takano, Yaoko, Tanaka, Junko, Hora, Kazuhiko, Nakazawa, Yasushi, Hasegawa, Naoki, Hanafusa, Norio, Hinoshita, Fumihiko, Morikane, Keita, Wakino, Shu, Nakamoto, Hidetomo, and Takemoto, Yoshiaki

Published
2022
Full Text
View/download PDF

13. Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis

Author

Yoshifuji, Ayumi, Toda, Masataro, Ryuzaki, Munekazu, Kikuchi, Kan, Kawai, Toru, Sakai, Ken, Oyama, Emi, Koinuma, Masayoshi, Katayama, Kazuhiko, Uehara, Yuki, Ohmagari, Norio, Kanno, Yoshihiko, Kon, Hirofumi, Shinoda, Toshio, Takano, Yaoko, Tanaka, Junko, Hora, Kazuhiko, Nakazawa, Yasushi, Hasegawa, Naoki, Hanafusa, Norio, Hinoshita, Fumihiko, Morikane, Keita, Wakino, Shu, Nakamoto, Hidetomo, and Takemoto, Yoshiaki

Published
2022
Full Text
View/download PDF

14. Coronavirus disease 2019 vaccination effectiveness based on the 2021 Japanese dialysis registry.

Author

Sugawara, Yuka, Iwagami, Masao, Kikuchi, Kan, Hashiba, Toyohiro, Yabushita, Sayaka, Ryuzaki, Munekazu, and Nangaku, Masaomi

Subjects
VACCINE effectiveness, VACCINATION status, COVID-19, JAPANESE people, VACCINATION
Abstract

Aim: The effectiveness of the coronavirus disease (COVID‐19) vaccine in Japanese patients undergoing haemodialysis has previously not been evaluated on a large scale. We analyzed data from the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR), covering nearly all Japanese patients undergoing dialysis (~95% coverage), to examine the association between COVID‐19 vaccination and infection or mortality. Methods: We used data from the JRDR end‐of‐year surveys conducted in 2020 and 2021, including information on the COVID‐19 vaccination and infection months. COVID‐19 infection incidence and its associated mortality rates based on vaccination status (time updated) and odds ratio (OR) (vaccinated vs. unvaccinated) were estimated monthly from April 2021, when vaccination commenced in Japan. Results: COVID‐19 infection analysis included 228 865 patients (215 941 vaccinated and 12 924 unvaccinated patients at the end of 2021). The age‐ and sex‐adjusted ORs (aORs) were significantly lower in August, September, October and November 2021, especially in September (aOR [95% confidence interval (CI)]: 0.25 [0.18–0.36]). Additional adjustments for past medical history and laboratory results rarely affected these results. Similarly, in the COVID‐19‐related mortality analysis with 228 731 patients, including 216 781 vaccinated and 11 950 unvaccinated at the end of 2021, COVID‐19‐related mortality risk was significantly lower in the vaccinated group in August, September, October and November (aOR [95% CI]: August, 0.32 [0.12–0.84], September, 0.04 [0.01–0.11]; October, 0.10 [0.01–0.81]; November, 0.05 [0.00–0.79]). Conclusion: In Japanese patients undergoing haemodialysis, the first or second COVID‐19 vaccine dose was significantly associated with decreased COVID‐19 infection and mortality rates, suggesting its effectiveness in this population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Usefulness of glycated albumin as a predictor of mortality in chronic hemodialysis patients with diabetes: a multi-center, prospective cohort study

Author

Hanai, Ko, Akamatsu, Makoto, Fujimori, Aki, Higashi, Harumichi, Horie, Yumiko, Itaya, Yoshiaki, Ito, Minoru, Kanamaru, Tomoko, Kawaguchi, Hiroshi, Kikuchi, Kan, Kobayashi, Hideo, Komatsu, Machiko, Kubota, Takao, Kudo, Kenichi, Kurihara, Satoshi, Masakane, Ikuto, Mera, Junichiro, Mizuiri, Sonoo, Moriyama, Kimiko, Nagasawa, Junichiro, Nagata, Sumiyo, Nakagawa, Yoshihiko, Nakazato, Satoshi, Nishi, Takahiro, Noma, Yoshihiko, Odaguchi, Naoyuki, Okuno, Senji, Osada, Shiwori, Ozasa, Hisashi, Sato, Sumihiko, Sawada, Tokihiko, Shimajiri, Tsuyako, Shimamoto, Yukiko, Suda, Masakazu, Suzuki, Toshihide, Suzuki, Hiromichi, Takahashi, Maki, Takahashi, Hajime, Takahashi, Toshimasa, Takebayashi, Yoshihiro, Takeda, Masanobu, Tamura, Hiroyuki, Tanaka, Yoshiko, Tokunaka, Sohei, Tsuda, Shinji, Ueda, Mio, Yamaguchi, Ichiro, Yamamoto, Hirohisa, Uchigata, Yasuko, and Babazono, Tetsuya

Published
2020
Full Text
View/download PDF

20. Association between Timing of Vascular Access Creation and Mortality in Patients Initiating Hemodialysis: A Nationwide Cohort Study in Japan.

Author

Murakami, Minoru, Fujii, Naohiko, Kanda, Eiichiro, Kikuchi, Kan, Wada, Atsushi, Hamano, Takayuki, and Masakane, Ikuto

Subjects
ARTERIOVENOUS fistula, ARTERIAL catheterization, MORTALITY, COHORT analysis, HEMODIALYSIS patients
Abstract

Introduction: The optimal time for vascular access (VA) creation remains controversial. Methods: We conducted a cohort study using data from the Japanese Society for Dialysis Therapy Renal Data Registry. Adult patients who started receiving hemodialysis in 2007 and had a permanent VA created were included. The exposure of interest was the timing of VA creation, categorized into three groups: early VA creation (defined as creation at least 4 months before hemodialysis initiation), just prior VA creation (creation between 1 and 3 months before hemodialysis initiation), and late VA creation (creation within 1 month of or after hemodialysis initiation). Cox regression analyses were used to compare 1-year all-cause mortality, with late VA creation as the reference group. Owing to the violations of the proportional hazards assumptions, the follow-up period was divided into "early" (1–4 months follow-up) and "late" (5–12 months follow-up) periods. Results: Overall, 1,280 (15.4%) of 8,322 patients died. Both early creation and just prior creation were associated with lower all-cause mortality in the early period compared with late creation. In the late period, the hazard ratios (HRs) for all-cause mortality decreased with earlier VA creation (adjusted HRs [95% confidence intervals]: 0.49 [0.35–0.67] for the early creation group and 0.63 [0.51–0.79] for the just prior creation group). Conclusion: Our study suggests that VA creation at least 1 month before hemodialysis initiation is associated with lower all-cause mortality in the early period, with earlier VA creation resulting in further mortality reduction in the late period. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Cellular and Humoral Immune Responses after Breakthrough Infection in Patients Undergoing Hemodialysis

Author

Toda, Masataro, primary, Yoshifuji, Ayumi, additional, Nakayama, Tetsuo, additional, Mise-Omata, Setsuko, additional, Oyama, Emi, additional, Uwamino, Yoshifumi, additional, Namkoong, Ho, additional, Komatsu, Motoaki, additional, Yoshimura, Akihiko, additional, Hasegawa, Naoki, additional, Kikuchi, Kan, additional, and Ryuzaki, Munekazu, additional

Published
2023
Full Text
View/download PDF

23. T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis

Author

Yoshifuji, Ayumi, Toda, Masataro, Ryuzaki, Munekazu, Oyama, Emi, Kikuchi, Kan, Kawai, Toru, Sakai, Ken, Koinuma, Masayoshi, Katayama, Kazuhiko, Yokoyama, Takashi, Uehara, Yuki, Ohmagari, Norio, Kanno, Yoshihiko, Kon, Hirofumi, Shinoda, Toshio, Takano, Yaoko, Tanaka, Junko, Hora, Kazuhiko, Nakazawa, Yasushi, Hasegawa, Naoki, Hanafusa, Norio, Hinoshita, Fumihiko, Morikane, Keita, Wakino, Shu, Nakamoto, Hidetomo, Takemoto, Yoshiaki, Yoshifuji, Ayumi, Toda, Masataro, Ryuzaki, Munekazu, Oyama, Emi, Kikuchi, Kan, Kawai, Toru, Sakai, Ken, Koinuma, Masayoshi, Katayama, Kazuhiko, Yokoyama, Takashi, Uehara, Yuki, Ohmagari, Norio, Kanno, Yoshihiko, Kon, Hirofumi, Shinoda, Toshio, Takano, Yaoko, Tanaka, Junko, Hora, Kazuhiko, Nakazawa, Yasushi, Hasegawa, Naoki, Hanafusa, Norio, Hinoshita, Fumihiko, Morikane, Keita, Wakino, Shu, Nakamoto, Hidetomo, and Takemoto, Yoshiaki

Abstract

Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.

Published
2023

26. T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis

Author

Yoshifuji, Ayumi, primary, Toda, Masataro, additional, Ryuzaki, Munekazu, additional, Oyama, Emi, additional, Kikuchi, Kan, additional, Kawai, Toru, additional, Sakai, Ken, additional, Koinuma, Masayoshi, additional, Katayama, Kazuhiko, additional, Yokoyama, Takashi, additional, Uehara, Yuki, additional, Ohmagari, Norio, additional, Kanno, Yoshihiko, additional, Kon, Hirofumi, additional, Shinoda, Toshio, additional, Takano, Yaoko, additional, Tanaka, Junko, additional, Hora, Kazuhiko, additional, Nakazawa, Yasushi, additional, Hasegawa, Naoki, additional, Hanafusa, Norio, additional, Hinoshita, Fumihiko, additional, Morikane, Keita, additional, Wakino, Shu, additional, Nakamoto, Hidetomo, additional, and Takemoto, Yoshiaki, additional

Published
2023
Full Text
View/download PDF

31. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID‐19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.

Author

Kikuchi, Kan, Nangaku, Masaomi, Ryuzaki, Munekazu, Yamakawa, Tomoyuki, Ota, Yoshihiro, Hanafusa, Norio, Sakai, Ken, Kanno, Yoshihiko, Ando, Ryoichi, Shinoda, Toshio, Wakino, Shu, Nakamoto, Hidetomo, Takemoto, Yoshiaki, and Akizawa, Tadao

Subjects
COVID-19, MOLNUPIRAVIR, SARS-CoV-2 Omicron variant, HEMODIALYSIS patients, COVID-19 pandemic
Abstract

Introduction: In the present study, the efficacy of sotrovimab and molnupiravir in dialysis patients with COVID‐19 was investigated using a registry of COVID‐19 in Japanese dialysis patients. Methods: Dialysis patients with confirmed SARS‐CoV‐2 during the COVID‐19 (Omicron BA.1 and BA.2) pandemic were analyzed. Patients were classified into four treatment groups: molnupiravir monotherapy (molnupiravir group), sotrovimab monotherapy (sotrovimab group), molnupiravir and sotrovimab combination therapy (combination group), and no antiviral therapy (control group). The mortality rates in the four groups were compared. Results: A total of 1480 patients were included. The mortality of the molnupiravir, sotrovimab, and combination groups were significantly improved compared to the control group (p < 0.001). Multivariate analysis indicated that antiviral therapy improves the survival of dialysis patients with COVID‐19 (hazard ratio was 0.184 for molnupiravir, 0.389 for sotrovimab, and 0.254 for combination groups, respectively). Conclusion: Sotrovimab showed efficacy in Omicron BA.1 but attenuated in BA.2. Molnupiravir also showed efficacy in BA.2, suggesting administration of molnupiravir would be important. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. T-cell Response and Antibody Production by Booster COVID-19 Vaccination in Japanese Patients with Chronic Kidney Disease Treated with Hemodialysis

Author

Yoshifuji, Ayumi, primary, Toda, Masataro, additional, Ryuzaki, Munekazu, additional, Oyama, Emi, additional, Kikuchi, Kan, additional, Kawai, Toru, additional, Sakai, Ken, additional, Koinuma, Masayoshi, additional, Katayama, Kazuhiko, additional, Uehara, Yuki, additional, Ohmagari, Norio, additional, Kanno, Yoshihiko, additional, Kon, Hirofumi, additional, Tanaka, Junko, additional, Shinoda, Toshio, additional, Takano, Yaoko, additional, Hora, Kazuhiko, additional, Nakazawa, Yasushi, additional, Hasegawa, Naoki, additional, Hanafusa, Norio, additional, Hinoshita, Fumihiko, additional, Morikane, Keita, additional, Wakino, Shu, additional, Nakamoto, Hidetomo, additional, and Takemoto, Yoshiaki, additional

Published
2022
Full Text
View/download PDF

40. Effectiveness of SARS‐CoV‐2 vaccines on hemodialysis patients in Japan: A nationwide cohort study.

Author

Kikuchi, Kan, Nangaku, Masaomi, Ryuzaki, Munekazu, Yamakawa, Tomoyuki, Yoshihiro, Ota, Hanafusa, Norio, Sakai, Ken, Kanno, Yoshihiko, Ando, Ryoichi, Shinoda, Toshio, Wakino, Shu, Nakamoto, Hidetomo, Takemoto, Yoshiaki, and Akizawa, Tadao

Subjects
COVID-19 vaccines, VACCINE effectiveness, HEMODIALYSIS patients, BREAKTHROUGH infections, COHORT analysis
Abstract

Introduction: This study compared the outcomes of dialysis patients who received SARS‐CoV‐2 vaccine with those who did not use data from the Japanese COVID‐19 registry. Methods: A total of 1260 dialysis patients with confirmed positive SARS‐CoV‐2 infection was included in this study. Patients were divided into two groups: patients who experienced breakthrough infection and those who were unvaccinated. The need of oxygen supplementation and mortality risks were compared using multivariate logistic regression analysis. Results: The mortality rate was 24.2% in unvaccinated patients and 8.6% in breakthrough patients. The odds ratio of need of oxygen supplementation in the breakthrough patients relative to unvaccinated patients was 0.197. The hazard ratio of mortality in the breakthrough patients relative to unvaccinated patients was 0.464. Conclusion: Our prospective observational study showed that SRAS‐CoV‐2 vaccination in hemodialysis patients is vital for reducing need of oxygen supplementation and mortality risk. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Additional file 1 of Infection prevention measures for patients undergoing hemodialysis during the COVID-19 pandemic in Japan: a nationwide questionnaire survey

Author

Sugawara, Yuka, Iwagami, Masao, Kikuchi, Kan, Yoshida, Yoko, Ando, Ryoichi, Shinoda, Toshio, Ryuzaki, Munekazu, Nakamoto, Hidetomo, Sakai, Ken, Hanafusa, Norio, Kashihara, Naoki, and Nangaku, Masaomi

Abstract

Additional file 1: Supplementary Table 1.Implementation status of infection prevention measures at each dialysis facility, before and after the COVID-19 pandemic occurred, by facility type. Supplementary Table 2. Percentages experiencing shortages of personal protective equipment due to pandemic, by facility type. Supplementary Table 3. Percentages of the availability of various isolation measures for suspected/diagnosed COVID-19 cases, by facility type.

Published
2021
Full Text
View/download PDF

48. Usefulness of glycated albumin as a predictor of mortality in chronic hemodialysis patients with diabetes: a multi-center, prospective cohort study

Author

HANAI, Ko, AKAMATSU, Makoto, FUJIMORI, Aki, HIGASHI, Harumichi, HORIE, Yumiko, ITAYA, Yoshiaki, ITO, Minoru, KANAMARU, Tomoko, KAWAGUCHI, Hiroshi, KIKUCHI, Kan, KOBAYASHI, Hideo, KOMATSU, Machiko, KUBOTA, Takao, KUDO, Kenichi, KURIHARA, Satoshi, MASAKANE, Ikuto, MERA, Junichiro, MIZUIRI, Sonoo, MORIYAMA, Kimiko, NAGASAWA, Junichiro, NAGATA, Sumiyo, NAKAGAWA, Yoshihiko, NAKAZATO, Satoshi, NISHI, Takahiro, NOMA, Yoshihiko, ODAGUCHI, Naoyuki, OKUNO, Senji, OSADA, Shiwori, OZASA, Hisashi, SATO, Sumihiko, SAWADA, Tokihiko, SHIMAJIRI, Tsuyako, SHIMAMOTO, Yukiko, SUDA, Masakazu, SUZUKI, Toshihide, SUZUKI, Hiromichi, TAKAHASHI, Maki, TAKAHASHI, Hajime, TAKAHASHI, Toshimasa, TAKEBAYASHI, Yoshihiro, TAKEDA, Masanobu, TAMURA, Hiroyuki, TANAKA, Yoshiko, TOKUNAKA, Sohei, TSUDA, Shinji, UEDA, Mio, YAMAGUCHI, Ichiro, YAMAMOTO, Hirohisa, UCHIGATA, Yasuko, BABAZONO, Tetsuya, HANAI, Ko, AKAMATSU, Makoto, FUJIMORI, Aki, HIGASHI, Harumichi, HORIE, Yumiko, ITAYA, Yoshiaki, ITO, Minoru, KANAMARU, Tomoko, KAWAGUCHI, Hiroshi, KIKUCHI, Kan, KOBAYASHI, Hideo, KOMATSU, Machiko, KUBOTA, Takao, KUDO, Kenichi, KURIHARA, Satoshi, MASAKANE, Ikuto, MERA, Junichiro, MIZUIRI, Sonoo, MORIYAMA, Kimiko, NAGASAWA, Junichiro, NAGATA, Sumiyo, NAKAGAWA, Yoshihiko, NAKAZATO, Satoshi, NISHI, Takahiro, NOMA, Yoshihiko, ODAGUCHI, Naoyuki, OKUNO, Senji, OSADA, Shiwori, OZASA, Hisashi, SATO, Sumihiko, SAWADA, Tokihiko, SHIMAJIRI, Tsuyako, SHIMAMOTO, Yukiko, SUDA, Masakazu, SUZUKI, Toshihide, SUZUKI, Hiromichi, TAKAHASHI, Maki, TAKAHASHI, Hajime, TAKAHASHI, Toshimasa, TAKEBAYASHI, Yoshihiro, TAKEDA, Masanobu, TAMURA, Hiroyuki, TANAKA, Yoshiko, TOKUNAKA, Sohei, TSUDA, Shinji, UEDA, Mio, YAMAGUCHI, Ichiro, YAMAMOTO, Hirohisa, UCHIGATA, Yasuko, and BABAZONO, Tetsuya

Published
2021

49. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study

Author

KIKUCHI, Kan, NANGAKU, Masaomi, RYUZAKI, Munekazu, YAMAKAWA, Tomoyuki, YOSHIHIRO, Oota, HANAFUSA, Norio, SAKAI, Ken, KANNO, Yoshihiko, ANDO, Ryoichi, SHINODA, Toshio, NAKAMOTO, Hidetomo, AKIZAWA, Tadao, KIKUCHI, Kan, NANGAKU, Masaomi, RYUZAKI, Munekazu, YAMAKAWA, Tomoyuki, YOSHIHIRO, Oota, HANAFUSA, Norio, SAKAI, Ken, KANNO, Yoshihiko, ANDO, Ryoichi, SHINODA, Toshio, NAKAMOTO, Hidetomo, and AKIZAWA, Tadao

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results